ReviewCancer immunology, immunotherapy : CII2012
Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy.
Review in Cancer immunology, immunotherapy : CII, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis.Frontiers in immunology · 2020Article
- Prostate cancer health disparities: An immuno-biological perspective.Cancer letters · 2018Article
- Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma.Frontiers in immunology · 2018Review
- Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33.Scientific reports · 2016Article
- Immune Infiltration and Prostate Cancer.Frontiers in oncology · 2015Review
- Immunosuppression via Tenascin-C.Oncoscience · 2015Article
- Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.Cancer immunology, immunotherapy : CII · 2014Article
- Trichomonas vaginalis homolog of macrophage migration inhibitory factor induces prostate cell growth, invasiveness, and inflammatory responses.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from orthotopic prostate cancer.Cancer immunology, immunotherapy : CII · 2013Article
- Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes.Frontiers in oncology · 2013Review
- A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer.Cancer immunology, immunotherapy : CII · 2013Article
- Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses.Oncoimmunology · 2013Article
- The new aspects of immunotherapy in prostate cancer.Cancer immunology, immunotherapy : CII · 2012Article
- Vitamin D-binding protein-derived macrophage-activating factor, GcMAF, and prostate cancer.Cancer immunology, immunotherapy : CII · 2012Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent FDA approval of the first therapeutic vaccine against prostate cancer has revitalized the public interest in the fields of cancer immunology and immunotherapy. Yet, clinical results are modest. A reason for this limited success may reside in the capacity of the tumor to convert inflammation in a tumor-promoting condition and eventually escape immune surveillance. Here we present the main known interactions between the prostate tumor and the immune system, showing how the malignancy can dodge the immune system by also exerting several immunosuppressive mechanisms. We also discuss experimental and clinical strategies proposed to counteract cancer immune evasion and emphasize the importance of implementing appropriate murine models like the transgenic adenocarcinoma of the mouse prostate model for investigating the biology of prostate cancer and novel immunotherapy approaches against it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.